Located in the San Francisco Bay Area, Celltheon has been serving the Biotherapeutics industry with innovation and dedication since its founding in 2012. Celltheon was founded as a California Corporation by Amita Goel, a leader in Cell Line Development and Expression Technologies, to develop the next generation in Cell Engineering technologies. Celltheon has patents, granted and pending, for its CHOK-1 derived SUPERCELL™ cell line and its unique DNA and RNA vector elements that are applicable for recombinant biotherapeutics such as Mabs, Difficult to Express Proteins (DEP) as well as for CAR-T, Gene Therapy and Cell Therapy applications. The CELLTHEON SMART™ Platform has been used to date in 100+ biotherapeutics for oncology, neurobiology and RA programs.